Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycyphagus domesticus allergen extract: in vivo allergenic potency determination in histamine equivalent prick units (HEP)
2007-000904-33Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Nov 2007
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glycyphagus domesticus allergen extract in allergic rhinitis (AR), allergic asthma and Hypersensitivity, sponsored by LETI Pharma. Primary endpoint: Wheal size. Started Nov 2007; status: completed.
02
Drugs
glycyphagus domesticus allergen extract
03
Conditions
allergic rhinitis (AR)allergic asthmaHypersensitivity
Beyond the preview
Go deeper on 2007-000904-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000904-33.